Medical Information

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Not a healthcare professional? Go to the patient or caregiver website.

ZYVOX®Highlights (linezolid)


These highlights do not include all the information needed to use ZYVOX safely and effectively. See full prescribing information for ZYVOX.

ZYVOX® (linezolid) injection, for intravenous use
ZYVOX® (linezolid) tablets, for oral use
ZYVOX® (linezolid) for oral suspension
Initial U.S. Approval: 2000


Indications and Usage, Limitations of Use (1.6)8/2020
Dosage and Administration, Intravenous Administration (2.2)8/2020
Warnings and Precautions, Risks in Patients with Phenylketonuria (5.10)8/2020


ZYVOX is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia (1.1); Community-acquired pneumonia (1.2); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis (1.3); Uncomplicated skin and skin structure infections (1.4); Vancomycin-resistant Enterococcus faecium infections. (1.5)

Limitations of Use (1.6):

  • ZYVOX is not indicated for the treatment of Gram-negative infections.
  • The safety and efficacy of ZYVOX formulations given for longer than 28 days have not been evaluated in controlled clinical trials.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX formulations and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.7)


Dosage, Route, and Frequency of Administration
InfectionPediatric Patients
(Birth through 11 years of Age)
Adults and Adolescents
(12 years and Older)
Nosocomial pneumonia 10 mg/kg intravenous or oral every 8 hours600 mg intravenous or oral every 12 hours10 to 14
Community-acquired pneumonia, including concurrent bacteremia
Complicated skin and skin structure infections
Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia10 mg/kg intravenous or oral every 8 hours600 mg intravenous or oral every 12 hours 14 to 28
Uncomplicated skin and skin structure infectionsless than 5 yrs: 10 mg/kg oral every 8 hours
5–11 yrs: 10 mg/kg oral every 12 hours
Adults: 400 mg oral every 12 hours
Adolescents: 600 mg oral every 12 hours
10 to 14


  • Injection: 200 mg/100 mL (2 mg/mL) and 600 mg/300 mL (2 mg/mL) linezolid. (3)
  • Tablet: 600 mg linezolid. (3)
  • For oral suspension: 100 mg of linezolid per each 5 mL. (3)


  • Known hypersensitivity to linezolid or any of the other product components. (4.1)
  • Patients taking any monoamine oxidase inhibitors (MAOI) or within two weeks of taking an MAOI. (4.2)


  • Myelosuppression: Monitor complete blood counts weekly. Consider discontinuation in patients who develop or have worsening myelosuppression. (5.1)
  • Peripheral and optic neuropathy: Reported primarily in patients treated for longer than 28 days. If patients experience symptoms of visual impairment, prompt ophthalmic evaluation is recommended. (5.2)
  • Serotonin syndrome: Patients taking serotonergic antidepressants should receive ZYVOX only if no other therapies are available. Discontinue serotonergic antidepressants and monitor patients for signs and symptoms of both serotonin syndrome and antidepressant discontinuation. (5.3)
  • A mortality imbalance was seen in an investigational study in linezolid-treated patients with catheter-related bloodstream infections. (5.4)
  • Clostridioides difficile-Associated Diarrhea: Evaluate if diarrhea occurs. (5.5)
  • Potential interactions producing elevation of blood pressure: monitor blood pressure. (5.6)
  • Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (5.9)
  • Phenylketonuria: ZYVOX for oral suspension contains phenylalanine which can be harmful to patients with phenylketonuria. (5.10)


Most common adverse reactions (>5% of adult and/or pediatric patients treated with ZYVOX) include: diarrhea, vomiting, headache, nausea, and anemia. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or


Monoamine oxidase inhibitors and potential for interaction with adrenergic and serotonergic agents. (4.2, 5.3, 5.6, 7, 12.3)


Revised: 8/2020

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event